 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
ARTICLES |
1 Professor of Pharmacy, College of Pharmacy, Ferris State University, Bronson Methodist Hospital, Kalamazoo, MI
2 Associate Professor of Pharmacy, College of Pharmacy, Ferris State University, Bronson Methodist Hospital
* To whom correspondence should be addressed. E-mail: vandenbh{at}bronsonhg.org.
 |
Abstract |
|---|
OBJECTIVE: To identify and evaluate available data on pediatric echinocandin use.
DATA SOURCES: A PubMed search, limited to English-language articles, was conducted (1990-August 2009) using the search terms echinocandin, pediatric, child, pharmacokinetics, caspofungin, micafungin, and anidulafungin. Additional articles were retrieved from citations of selected references.
STUDY SELECTION AND DATA EXTRACTION: Relevant information on the pharmacology, pharmacokinetics, efficacy, and safety of echinocandins in children was selected. Clinical trials, retrospective reviews, and case series were identified and evaluated. Data from these sources were included in this review.
DATA SYNTHESIS: Caspofungin is the only echinocandin approved by the Food and Drug Administration for use in children. Pediatric pharmacokinetics has been evaluated with all 3 echinocandins but is limited with anidulafungin. Micafungin is the most well-studied agent in prospective clinical trials for antifungal prophylaxis in stem cell transplantation and treatment of invasive fungal infections. Caspofungin has been studied prospectively for febrile neutropenia and treatment of invasive fungal infections, but most published data are from retrospective reviews or case reports. One case report of anidulafungin for neonatal candidiasis has been published. The role of echinocandins in the management of invasive pediatric fungal infections has expanded. Micafungin and caspofungin are recommended as primary or alternative treatment of candidemia and esophageal or invasive candidiasis, and as salvage therapy for invasive aspergillosis. Micafungin is recommended for neutropenic prophylaxis in stem cell transplantation, while caspofungin may be used in febrile neutropenia as an alternative to azoles. Dosing has been well established for caspofungin only in children 3 months of age and above. Anidulafungin should be avoided in children until more pharmacokinetic and clinical data become available.
CONCLUSIONS: Further comparative trials are needed to more clearly define the role of echinocandins, either as monotherapy or in combination for difficult-to-treat infections, in the pediatric population.
Key Words: anidulafungin, caspofungin, echinocandins, micafungin, pediatrics.
Reprints: Dr. VandenBussche, Ferris State University/Bronson Methodist Hospital, Pharmacy Department, 601 John St., Box #56, Kalamazoo, MI 49007, fax 269/341-7861, vandenbh@bronsonhg.org
Financial disclosure: None reported
 |
 |
 |
 |
 |
 |
 |
